Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRüegg, Linda
dc.contributor.authorKramer, Malte
dc.contributor.authorPluma Sanjurjo, Andrea
dc.contributor.authorHAMROUN, SABRINA
dc.contributor.authorCecchi, Irene
dc.contributor.authorPerez, Luis
dc.date.accessioned2025-10-31T07:30:55Z
dc.date.available2025-10-31T07:30:55Z
dc.date.issued2025-09
dc.identifier.citationPluma A, Hamroun S, Rüegg L, Cecchi I, Kramer M, Perez-Garcia LF, et al. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis. 2025 Sep;84(9):1561–90.
dc.identifier.issn0003-4967
dc.identifier.urihttp://hdl.handle.net/11351/13990
dc.descriptionAntirheumatic drugs; Reproduction; Pregnancy
dc.description.abstractObjectives This study aimed to summarise and update evidence to inform the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation. Methods A systematic literature review (SLR) was performed, including keywords on reproduction, adverse pregnancy outcomes (APOs), and lactation. Two appraised SLRs were the basis for the SLR on drug safety in men. If sufficient data were available, a meta-analysis was performed on maternal drug exposure and the risk of APOs. Results Of 6680 screened articles, 255 were included in the final analysis. In pregnancy, most evidence was available for biologic disease-modifying antirheumatic drugs (bDMARDs). Meta-analyses with adjusted risk estimates did not reveal APOs or serious infant infections to be associated with tumour necrosis factor inhibitor (TNFi) use. Data on non-TNFi bDMARDs did not raise concerns. In bDMARD-exposed infants, no serious adverse effects to rotavirus live vaccination were reported. Safety of Bacille Calmette–Guérin vaccination in TNFi-exposed infants could be a concern in the first 6 months of life. Regarding oral glucocorticoids, the SLR and meta-analysis using adjusted risk estimates found a dose-dependent association with an increased risk of preterm birth. Nonsteroidal anti-inflammatory drug use could reversibly reduce fecundability. Concerning lactation, available data on various bDMARDs was reassuring. In male patients, available evidence on methotrexate and most other drugs did not reveal adverse effects on sperm quality or birth outcomes. Cyclophosphamide remains the only drug that causes a dose-dependent irreversible infertility. Conclusions This SLR provides up-to-date evidence to guide the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of the Rheumatic Diseases;84(9)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEmbaràs
dc.subjectAlletament
dc.subjectReumatisme - Tractament
dc.subjectAntireumàtics - Ús terapèutic
dc.subjectReproducció
dc.subject.meshRheumatic Diseases
dc.subject.mesh/drug therapy
dc.subject.meshReproduction
dc.subject.meshPregnancy
dc.subject.meshLactation
dc.subject.meshAntirheumatic Agents
dc.titleAntirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ard.2025.02.021
dc.subject.decsenfermedades reumáticas
dc.subject.decs/farmacoterapia
dc.subject.decsreproducción
dc.subject.decsembarazo
dc.subject.decslactancia
dc.subject.decsantirreumáticos
dc.relation.publishversionhttps://doi.org/10.1016/j.ard.2025.02.021
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pluma A] Servei de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hamroun S] Department of Rheumatology, Pontoise Hospital, Pontoise, Paris, France. [Rüegg L] Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland. [Cecchi I] University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERNReconnect, and RITA-ERN Member) with Nephrology and Dialysis Unit, University of Turin, Turin, Italy. Center of ImmunoRheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy. Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. [Kramer M] Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany. [Perez-Garcia LF] Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
dc.identifier.pmid40240264
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record